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SummAry – to review the outcome of vagus nerve stimulation (vnS) therapy in all implanted 
Slovenian patients with drug-resistant epilepsy, data on 48 patients implanted between 2001 and 2015 
were obtained retrospectively from medical records. The outcome was assessed in 2016. Out of 48 
patients, 39 responded at follow up. The seizure frequency was reduced in 18 (46.2%) patients; 13 
(33.3%) of them reported ≥50% reduction after 12 months of therapy. The responder rate was higher 
among patients implanted before the age of six years. ictal severity decreased in 22 (56.4%), seizure 
duration in 19 (48.7%) and post-ictal recovery time in 22 (56.4%) patients. favorable effects on the 
quality of life (QOl) were improved alertness in 33.3%, concentration in 41.0%, energy and mood in 
38.5%, and memory in 17.9% of patients. reduced seizure burden and improved QOl were more 
often observed in patients implanted at a younger age. Shorter duration of epilepsy was significantly 
associated with QOl improvement. Adverse effects were transient. Overall positive effects showed 
vnS to be a safe, well-tolerated and effective adjunctive treatment in most severe drug-resistant epi-
lepsy patients. implantation at a younger age and shorter duration of epilepsy before implantation 
could be important predictors of better outcome.
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Introduction
Epilepsy is one of the most prevalent neurological 
conditions and a significant cause of disability and 
mortality. it is estimated to affect 50-70 million people 
worldwide1. despite many antiepileptic drugs (AEds), 
20%-30% of patients have drug-resistant epilepsy2,3.
vagus nerve stimulation (vnS) therapy was ap-
proved in 1997 as an adjunctive treatment for patients 
with drug-resistant epilepsy, who are not suitable can-
didates for epilepsy surgery or had insufficient benefit 
from it4,5. Compared to the new AEds, vnS therapy 
has similar or even better long-term efficacy, with con-
tinued improvement in seizure reduction for up to two 
years after implantation6. vnS therapy is associated 
with significantly greater improvement in health-re-
lated quality of life (QOl) over best medical practice 
alone in patients with drug-resistant focal epilepsy7. 
Jennum et al. in a case-control study of 101 patients 
showed that implantation of vnS was associated with 
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reduction of hospital services and epilepsy-related pre-
scription medications8. not only may vnS reduce the 
seizure frequency without negatively affecting behav-
ior or cognitive functions, it also reduces seizure sever-
ity, duration and post-ictal recovery time9,10. Some 
studies suggest that the effectiveness of vnS increases 
with treatment duration9-13. however, vnS treatment 
is also known to cause some adverse effects9-17.
The aim of our study was to determine the outcome 
of vnS therapy with emphasis on seizure burden, 
QOl and adverse effects, focusing in particular on the 
impact of age at vnS implantation and duration of 
epilepsy before the implantation as possible predictors 
of treatment efficacy.
Patients and Methods
We reviewed the files of all 48 Slovenian patients 
who had a vnS device implanted until 2015. Since 
vnS implantation in Slovenia started in January 2005, 
three of our patients were implanted abroad before 
2005, while 45 were implanted in Slovenia from Janu-
ary 2005 to december 2015. All patients were im-
planted and regularly followed up at the university 
medical Centre ljubljana. All implantations were 
done by two neurosurgeons, trained by official product 
manager (Cyberonics) supervisior, so that correct sur-
gical technique was achieved. The vnS-related data, 
possible adverse effects and AEds were routinely doc-
umented at regular outpatient visits.
We collected the following data from medical re-
cords: gender, date of birth, age at seizure onset, epi-
lepsy etiology, dominant seizure type, age at vnS im-
plantation, duration of vnS treatment, time elapsed 
from the first seizure to vnS implantation, epilepsy-
related surgery, diagnosis of behavioral disorders, and 
verbal communication status. The etiology of epilepsy 
was reclassified according to the ilAE latest guide-
lines as genetic, structural, metabolic, immune, infec-
tious or unknown18. regarding the dominant or most 
disabling seizure type, patients were divided into two 
groups: focal and generalized.
during the follow up in 2016, the questionnaire 
was sent to all patients, their parents or guardians. 
Eight of the 48 patients or their parents declined to 
participate, one patient died from a cause unrelated to 
epilepsy. The questionnaire included questions on the 
following characteristics: most disabling/dominant 
seizure type frequency, seizure severity and duration, 
post-ictal recovery time after vnS treatment – wheth-
er the characteristics improved, worsened, or did not 
change. The monthly seizure frequency after vnS im-
plantation was calculated from the patient seizure dia-
ries before and at three, six and twelve months after 
the onset of stimulation, if available. With the purpose 
of comparing our results to other studies, we assessed 
the rate of overall seizure reduction after 12 months of 
vnS implantation. The information was collected 
from medical records. Patients were considered re-
sponders if they had ≥50% reduction in seizure fre-
quency.
The QOl was assessed by the following parame-
ters: alertness, concentration, energy, memory, mood 
and progress in schoolwork. Parents or guardians as-
sessed QOl changes as better, unchanged or worse 
than before vnS.
to study the impact of age at implantation and du-
ration of epilepsy before implantation on seizure-re-
lated parameters and QOl, we divided patients into 
different age groups to check where significant differ-
ences appeared. We reported results only if the obser-
vation was positive.
Table 1. Epilepsy etiologies in all VNS implanted 
Slovenian patients (N=48)
Etiology of epilepsy n
Perinatal hypoxic ischemic encephalopathy 7
Congenital cerebrovascular insult 2
meningoencephalitis 5
focal cortical dysplasia 4
dravet syndrome 2
CdKl5 mutation 1











vnS = vagus nerve stimulation
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data on adverse effects immediately after vnS im-
plantation were gathered from the questionnaire. in-
formation on their presence in the following months 
was obtained from medical records.
The Slovenian national medical Ethics Commit-
tee approved the study and a written informed consent 
was obtained from all participants and their parents or 
legal guardians before inclusion in the study.
data were presented as a mean, standard deviation 
and range for continuous variables, and as frequencies 
for categorical variables. for graphical demonstration 
of the possible association between treatment dura- 
tion and efficacy, the change in seizure frequency over 
time was calculated with generalized linear modeling 
using a bootstrap method. When determining statisti-
cal significance of proportions, we used the χ2 pro-
portions test. values of p<0.050 were considered sta-
tistically significant. All statistical analyses were car-
ried out by free accessible statistical program r+ (ver-
sion 3.3.2).
Table 2. Demographic and clinical features of VNS patients (N=39)
Clinical feature n (%) mean ± Sd range
gender male 21 (53.8%)
female 18 (46.2%)
Age at seizure onset (years) 4.8±6.3 0-24
Age at vnS implantation (years) 18.1±14.2 3-56
time elapsed from first seizure  
to vnS implantation (years) 13.4±11.3 2.5-53.5
time elapsed from vnS 
implantation to follow up (years) 7.2±3.6 1.6-15




dominant seizure type focal 27 (69.2%)
generalized 12 (30.8%)
history of epilepsy-related surgical 
procedure yes 6 (15.4%)
no 33 (84.6%)
number of different AEds prior  
to vnS implantation ≤5 10 (25.6%)
6-9 20 (51.3%)
≥10 9 (23.1%)
behavioral disorders prior to vnS yes 17 (43.6%)
no 21 (53.8 %)
unknown 1 (2.6 %)
verbal communication status  
prior to vnS
Appropriately developed  
for chronologic age 12 (30.8%)
not appropriately developed  
for chronologic age 13 (33.3%)
not capable of verbal communication 12 (30.8%) 
unknown 2 (5.1%)
vnS = vagus nerve stimulation; AEd = antiepileptic drug
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Results
in total, 45 patients with drug-resistant epilepsy 
were implanted vnS in Slovenia from January 2005 to 
december 2015, while three our patients had been im-
planted before 2005 abroad. Epilepsy etiologies in all 
48 patients are enlisted in table 1.
in the follow up study in 2016, 39 (81.2%) patients 
agreed to participate. Their clinical features are shown 
in table 2.
Fig. 1. Percentages of patients with different seizure-related parameter outcomes  
after VNS implantation as reported at follow up in 2016.
vnS = vagus nerve stimulation
Fig. 2. Percentages of patients with improvement of seizure-related parameters  
in three different age groups at VNS implantation.
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Fig. 4. Percentages of patients having showed improvement in QOL parameters in different 
age groups at VNS implantation.
vnS = vagus nerve stimulation; QOl = quality of life
Fig. 3. Seizure frequencies in 16 patients before  
and 3, 6 and 12 months after the onset of VNS  
(line represents the mean seizure frequency; shaded area 
denotes 95% confidence interval; the change in seizure 
frequency over time was calculated with generalized 
linear modeling using a bootstrap method).
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The effect of VNS on seizure burden
At follow up in 2016, an overall decrease in seizure 
frequency was seen in 18 (46.2%), ictal severity im-
proved in 22 (56.4%), seizure duration in 19 (48.7%) 
and post-ictal recovery time decreased in 22 (56.4%) 
patients (fig. 1).
Out of 39 patients, 13 (33.3%) had ≥50% reduction 
in seizure frequency 12 months after vnS implanta-
tion. The responder rate was higher in those implanted 
before the age of six years (71.4%) compared to pa-
tients implanted later (25.0% of responders).
The impact of age at vnS implantation on differ-
ent seizure-related parameter outcomes among the 
three age groups is illustrated in figure 2. reduction 
in all four parameters was more frequently reported in 
the youngest group.
Positive correlation was found between longer 
vnS treatment and its efficacy. in 16 patients having 
kept precise seizure diaries after vnS therapy onset, 
seizure frequencies were analyzed as a proportion of 
their maximum reported seizure frequency. The re-
ported seizure frequencies before vnS and 3, 6 and 12 
months after the onset of stimulation were compared 
(fig. 3). The overall mean seizure frequency 3 months 
after implantation fell to 69.3% (95% Ci, 34.3%-
92.3%), after 6 months to 46.3 % (95% Ci, 14.6%-
79.5%) and after 12 months to 24.8% (95% Ci, 4.5%-
59.0%) of the baseline value measured before vnS. 
The decline in seizure frequency after vnS was statis-
tically significant (χ2=21.3, df=3, p<0.001).
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Fig. 5. Percentages of patients having showed improvement in QOL parameters. Comparison of two groups according 
to duration of epilepsy before VNS implantation (<8 years and ≥8 years) revealed notable differences.
vnS = vagus nerve stimulation; QOl = quality of life
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The effect of VNS on QOL
According to the questionnaires, the following 
changes were reported by parents: increased alertness 
in 13 (33.3%), better concentration in 16 (41.0%), im-
proved energy and mood in 15 (38.5%), progress in 
schoolwork in nine (23.1%) and memory in seven 
(17.9%) of 39 patients. four QOl parameters (alert-
ness, concentration, energy and mood) were more fre-
quently improved in patients implanted before the age 
of six years (fig. 4).
Epilepsy duration before vnS therapy also seemed 
to affect QOl parameters in favor of those with ear-
lier implantation (fig. 5). A statistically significant dif-
ference between the two groups was observed in con-
centration (χ2=12.7, df=1, p<0.001), energy (χ2=14.7, 
df=1, p<0.001), mood (χ2=6.0, df=1, p<0.01) and prog-
ress in schoolwork (χ2=13.2, df=1, p<0.001).
Adverse effects
The following adverse effects were reported in 
medical records a few months after vnS implantation: 
hoarseness in 21 (53.8%), increased salivation in 14 
(35.9%), cough in 13 (33.3%), snoring in 11 (28.2%), 
cervical muscle spasm in ten (25.6%) and laryngeal 
pain in nine (23.1%) patients (fig. 6). At follow up in 
2016, all effects except for hoarseness during stimula-
tion were much milder or gone.
Discussion
We found that vnS therapy contributed to notable 
reduction of seizure burden in nearly half of patients 
(fig. 1), and 33% of our patients responded with ≥50% 
reduction of seizure frequency after 12 months of 
therapy, which is similar to many other studies9,10,12,17,19, 
while some authors have reported better efficacy16,20-23. 
The response rate in our patients should be considered 
from two aspects: firstly, the majority of our patients 
had severe drug-resistant epilepsy for a very long time 
before vnS, and some studies indicated that longer 
duration of epilepsy could be negatively correlated 
with the efficacy of vnS24. Secondly, intellectual dis-
ability prior to vnS therapy was present in 64% of our 
patients, and it has been published recently that vnS 
is less effective in children with intellectual disability25.
At follow up, the mean duration of vnS therapy in 
our group was 7.2 (Sd 3.6, range 1.6-15) years, long 
enough to cover most responders, as patients may have 
seizure reduction 3 to 5 years after vnS implanta-
tion26.
in addition to seizure frequency, we found im-
provements in other seizure-related parameters in 46% 
to 56% of our patients (fig. 1), which is comparable to 
other studies9,27.
Correlation between the age at vnS implantation 
and the outcome in our study showed that younger pa-
tients had better outcomes in all seizure parameters. 
There are some contradictory data published regarding 
this association. Elliott et al.22 and murphy et al.28 did 
not find any significant correlation, whereas ghaemi et 
al.29, lagae et al.24 and yu et al.23 report that a younger 
age at vnS implantation might be a positive predic-
tive factor for vnS efficacy. in our study, the percent-
age of patients with reduction in seizure frequency in 
the youngest age group was 71.4%, similar to the 
youngest group in a belgian study with 77% responder 
rate24. however, the number of cases in each age group 
in our study was rather small and with different etiol-
ogy, therefore, statistical analysis was not feasible. Ad-
ditional studies should elucidate the impact of age at 
vnS implantation and/or etiology itself on efficacy.
lagae et al. found that shorter duration of epilepsy 
before vnS might be an important predictor of effi-
cacy24. better results with earlier implantation during 
the first decade might also reflect the possible role of 
younger age with ongoing brain maturation interact-
ing with the epileptogenic processes, while vnS 
mechanisms, although not well understood yet, might 
raise the level of functional inhibitory networks30. in 
our study, shorter duration of epilepsy seemed to affect 
most QOl parameters with significant difference be-
tween the two groups observed in concentration, mood 
and schoolwork (fig. 4).
We found a positive correlation between longer 
vnS treatment and efficacy with reference to reduc-
tion in seizure frequency (fig. 3). Similar results have 
been reported by several authors9,10,12,17,20,31-33, but not 
by some others21. yu et al.23 showed this correlation to 
depend on the baseline median seizure frequency; 
those patients with high baseline seizure frequency 
achieved significant reduction at 12-month follow up, 
whereas in the low baseline seizure frequency group, 
the seizure frequency reduction was not significant. 
vnS has repeatedly been claimed to exert neuro-
modulatory effects with prolonged treatment rather 
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than as an immediate consequence of stimulation. 
long-term effectiveness suggests that vnS may work 
through re-modulation of networks towards a less ep-
ilepsy-prone state34.
At the beginning of vnS therapy era, the seizure 
frequency reduction was the only measure of its effi-
cacy. later, focus on QOl parameters has become an 
additional important issue in the management of 
drug-resistant epilepsy patients. We found positive ef-
fects of vnS therapy on most QOl parameters in 
one-third of patients, which is consistent with some 
other studies9-11,14,21,27,35. longer duration of poorly 
managed drug resistant epilepsy is a major factor in 
cognitive decline36. We found better results in the 
youngest age group with shorter duration of epilepsy, 
as positive changes in most parameters were noticed in 
patients implanted less than eight years after the onset 
of epilepsy. it remains unclear whether improvement 
in QOl is a result of stimulation itself or a beneficial 
effect of seizure alleviation. With better control of sei-
zures with vnS therapy in school and other public 
places, social acceptance of people with epilepsy might 
improve and reduce the level of stigma in our societ-
ies37.
Among vnS adverse effects (fig. 6), voice change 
was most frequently reported, and it serves as a marker 
of vnS function. The proportion of other adverse ef-
fects found in our group was quite similar to the fig-
ures published elsewhere9-12,14-16,23,28,33,35. most adverse 
effects in our patients were transitory and present 
mainly during the first three months after the onset of 
vnS stimulation, which is comparable to other stud-
ies11,12,14,21. none of our patients had vnS device re-
moved due to adverse effects, but it was removed in 
five patients due to its ineffectiveness, which is the 
most common reason for vnS device removal28,38.
Limitations
Our study had several limitations, the most impor-
tant being the small and very heterogeneous sample 
size, as well as retrospective and observational nature 
of the study. The medical records did not always pro-
vide detailed information on the frequency of several 
seizure types, severity and post-ictal recovery time, and 
this part of information was covered by questionnaires 
at follow up study.
improvements in QOl parameters in vnS treated 
patients could also be a consequence of natural evolu-
tion of epilepsy, and not exclusively a positive effect of 
vnS. however, it is not common that patients with 
long lasting severe drug-resistant epilepsy would 
achieve remission or important seizure frequency re-
duction by another AEd.
Conclusions
vnS therapy is a well-tolerated treatment option 
for drug-resistant epilepsy, which may reduce the bur-
den of seizures and improve the overall QOl. The ad-
verse effects are mild and mostly transitory. it seems 
that the seizures and QOl might improve more 
among patients with vnS implanted at a younger age 
and earlier after the onset of epilepsy. vnS therapy 
should therefore be considered early in the course of 
disease, including patients with intellectual disabilities, 
who are too often left with no further treatment 
 option.
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Sažetak
dJElOtvOrnOSt i POdnOŠlJivOSt tErAPiJE StimulACiJOm vAguSnOg ŽivCA (vnS)  
u SlOvEnSKih bOlESniKA S EPilEPSiJOm: mlAĐA dOb i KrAĆE trAJAnJE EPilEPSiJE  
mOŽE rEZultirAti bOlJim iShOdOm
A. Kavčič, N. Kajdič, Z. Rener-Primec, N. Krajnc i T. Žgur
Svrha istraživanja bila je utvrditi učinke liječenja slovenskih bolesnika s epilepsijom i implantiranim stimulatorom vagu-
snog živca (SvŽ). Podaci svih slovenskih bolesnika kojima je SvŽ implantiran od 2001. do 2015. godine prikupljeni su iz 
medicinske dokumentacije. u 2016. godini od 48 bolesnika sa SvŽ 39 ih je odgovorilo na upitnik o učinku liječenja. učesta-
lost napadaja smanjena je kod 18 (46,2%) bolesnika, od kojih je 13 (33,3%) izvijestilo o ≥50% smanjenju učestalosti napada-
ja nakon 12 mjeseci liječenja i to je bilo češće u bolesnika kojima je SvŽ implantiran prije dobi od šest godina. intenzitet 
napadaja smanjen je kod 22 (56,4%), trajanje napadaja kod 19 (48,7%), a trajanje postiktalnog perioda kod 22 (56,4%) bole-
snika. u procjeni kvalitete života zabilježeno je poboljšanje pozornosti kod 33,3%, koncentracije kod 41,0%, energije i raspo-
loženja kod 38,5%, pamćenja kod 17,9% bolesnika. Smanjenje opterećenja napadajima i poboljšanje kvalitete života bilo je 
češće kod bolesnika kojima je ranije implantiran SvŽ. Kraće trajanje epilepsije prije implantacije također je bilo statistički 
značajno povezano s poboljšanjem parametara kvalitete života. nuspojave SvŽ su bile prolazne. Stimulator vagusnog živca 
je sigurna i učinkovita metoda liječenja bolesnika s upornom epilepsijom. rana implantacija i kraće trajanje epilepsije prije 
implantacije mogući su prediktivni čimbenici za bolji ishod liječenja.
Ključne riječi: Vagus, stimulacija; Epilepsija; Kvaliteta života; Istraživanja s praćenjem; Napadaji; Slovenija
